KRAS and pancreatic ductal adenocarcinoma: In another study, the MDM2–p53 interaction inhibitor PXN822 alone or combined with topoisomerase II inhibitor can induce cell death in KRAS-mutated murine pancreatic ductal adenocarcinoma cells, regardless of the p53 status [107].